(Information sent by the signatory company)
Israel, February 1, 2023.
Distinguished surgeon and founder known for successfully bringing innovations in medical technology to market through acquisitions by large medical companies
Endoron Medical ("Endoron"), a medical device company developing an innovative solution for the endovascular repair of abdominal aortic aneurysms (AAAs), today announced that Professor Jacques Séguin will join its board of directors as Chairman.Séguin , Professor of Cardiac Surgery at the University of Paris, is a doctor in Biochemistry and History of Medicine and has more than 20 years of experience in performing more than 4,000 open-heart operations and is the author of more than 200 articles in journals peer-reviewed international medical procedures. Prof. Séguin is known for making lasting contributions to the field of medical technology through the development of innovative solutions, including the self-expanding TAVR procedure, developed by CoreValve, a company founded by him that was later acquired by Medtronic for over $800 million in 2009. The CoreValve Revascularization System it was the first TAVR (transcatheter aortic valve replacement) system to receive the CE mark in 2007 and has already helped 25,000 heart patients worldwide. Professor Séguin was also part of the original team of ReCor Medical, a renal denervation company founded by Sofinnova Partners and acquired by the Japanese company Otsuka in 2018. Both CoreValve and ReCor Medical were funded by Sofinnova Partners in the Series A phase. Professor Seguin also founded Stentys and is currently Chairman of Picardia, which are also companies backed by Sofinnova Partners, "I am honored to join Endoron in supporting the emergence of Aortoseal in clinical practice," he stated. "The technology developed by Endoron mimics the hand-sewn graft of open surgery and is well on its way to solving the number one problem in endovascular aneurysm repair: long-term durability. I am convinced that Endoron is bringing a revolutionary technology to the market for EVAR with a very disruptive approach." "We are proud and delighted to have Professor Seguin join our board as Chairman, at a pivotal time for the company," said Ronit Harpaz, Co-Founder and CEO of Endoron. "With his long and successful track record in the field of medical technology, Professor Séguin brings to Endoron in-depth knowledge and experience to help us advance our innovative technology into the clinic. We look forward to working together to offer AAA patients undergoing Endovascular Aneurysm Repair a Durable Sealing and Fixation Solution for Your Endograft Experience."[1] Investeurope.eu, "Corevalve", [accessed 21 Jan 2023] https://www.investeurope.eu /about-private-equity/private-equity-in-action/corevalve/About Endoron Medical Endoron Medical is a portfolio company of Sofinnova Partners, a leading European life sciences venture capital firm headquartered in Paris, London and Milan. The company received seed funding from Sofinnova MD Start, the company's in-house medtech accelerator. Endoron is developing an endovascular suturing device to prevent long-term complications in the treatment of abdominal aortic aneurysms. For more information, visit endoronmedical.com.
ContactContact name: Ronit HarpazContact description: CEO, Endoron MedicalContact telephone:
